Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer

Annals of Oncology

Volumn 21, Issue 3, 2009, Pages 466-473

  Nadler, Y ^a   Gonzalez A M ^b,c   Camp, R L ^a   Rimm, D L ^a   Kluger, H M ^a   Kluger, Y ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Grb7; HER2 neu; Prognosis; Therapeutic targets

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TISSUE MICROARRAY; TUMOR VOLUME; WESTERN BLOTTING;

EID: 77949581444     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp346     Document Type: Article

References (47)

1. Margolis B, Silvennoinen O, Comoglio F et al. High-efficiency expression/cloning of epidermal growth factor-receptor-binding proteins with Src homology 2 domains. Proc Natl Acad Sci U S A 1992; 89: 8894-8898.
2. Shen TL, Han DC, Guan JL. Association of Grb7 with phosphoinositides and its role in the regulation of cell migration. J Biol Chem 2002; 277: 29069-29077.
3. Daly RJ. The Grb7 family of signalling proteins. Cell Signal 1998; 10: 613-618.
4. Han DC, Shen TL, Guan JL. The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions. Oncogene 2001; 20: 6315-6321.
5. Holt LJ, Daly RJ. Adapter protein connections: the MRL and Grb7 protein families. Growth Factors 2005; 23: 193-201.
6. Shen TL, Guan JL. Grb7 in intracellular signaling and its role in cell regulation. Front Biosci 2004; 9: 192-200.
7. Pero SC, Daly RJ, Krag DN. Grb7-based molecular therapeutics in cancer. Expert Rev Mol Med 2003; 5: 1-11.
8. Margolis B. The GRB family of SH2 domain proteins. Prog Biophys Mol Biol 1994; 62: 223-244.
9. Cohen GB, Ren R, Baltimore D. Modular binding domains in signal transduction proteins. Cell 1995; 80: 237-248.
10. Pawson T, Gish GD, Nash P. SH2 domains, interaction modules and cellular wiring. Trends Cell Biol 2001; 11: 504-511.
11. Stein D, Wu J, Fuqua SA et al. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. Embo J 1994; 13: 1331-1340.
12. Gullick WJ. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer Suppl 1990; 5: 55-61.
13. Frantz JD, Giorgetti-Peraldi S, Ottinger EA, Shoelson SE. Human GRB-IRbeta/GRB10. Splice variants of an insulin and growth factor receptor-binding protein with PH and SH2 domains. J Biol Chem 1997; 272: 2659-2667.
14. Han DC, Shen TL, Miao H et al. EphB1 associates with Grb7 and regulates cell migration. J Biol Chem 2002; 277: 45655-45661.
15. Han DC, Shen TL, Guan JL. Role of Grb7 targeting to focal contacts and its phosphorylation by focal adhesion kinase in regulation of cell migration. J Biol Chem 2000; 275: 28911-28917.
16. Han DC, Guan JL. Association of focal adhesion kinase with Grb7 and its role in cell migration. J Biol Chem 1999; 274: 24425-24430.
17. Pawson T. SH2 and SH3 domains in signal transduction. Adv Cancer Res 1994; 64: 87-110.
18. Fiddes RJ, Campbell DH, Janes PW et al. Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J Biol Chem 1998; 273: 7717-7724.
19. Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004; 24: 4943-4954.
20. Tanaka S, Sugimachi K, Kawaguchi H et al. Grb7 signal transduction protein mediates metastatic progression of esophageal carcinoma. J Cell Physiol 2000; 183: 411-415.
21. Tanaka S, Mori M, Akiyoshi T et al. A novel variant of human Grb7 is associated with invasive esophageal carcinoma. J Clin Invest 1998; 102: 821-827.
22. Pero SC, Shukla GS, Cookson MM et al. Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. Br J Cancer 2007; 96: 1520-1525.
23. Kauraniemi P, Barlund M, Monni O, Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 2001; 61: 8235-8240.
24. Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol 2003; 163: 1979-1984.
25. Luoh SW. Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells. Cancer Genet Cytogenet 2002; 136: 43-47.
26. Bieche I, Onody P, Tozlu S et al. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003; 106: 758-765.
27. Vinatzer U, Dampier B, Streubel B et al. Expression of HER2 and the coamplified genes Grb7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res 2005; 11: 8348-8357.
28. Cobleigh MA, Tabesh B, Bitterman P et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005; 11: 8623-8631.
29. Bai T, Luoh SW. GRB-7 facilitates HER-2/neu-mediated signal transduction and tumor formation. Carcinogenesis 2008; 29: 473-479.
30. Kao J, Pollack JR. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 2006; 45: 761-769.
31. Pero SC, Oligino L, Daly RJ et al. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. J Biol Chem 2002; 277: 11918-11926.
32. Tanaka S, Pero SC, Taguchi K et al. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst 2006; 98: 491-498.
33. Yakes FM, Chinratanalab W, Ritter CA et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62: 4132-4141.
34. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
35. Dolled-Filhart M, McCabe A, Giltnane J et al. Quantitative in situ analysis of betacatenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006; 66: 5487-5494.
36. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8: 1323-1327.
37. Nadler Y, Camp RL, Giltnane JM et al. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 2008; 10: R35.
38. Peacock J. Two-dimensional goodness-of-fit testing in astronomy. Mon Not R Astr Soc 1983; 202: 615-627.
39. Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-1682.
40. Fisher B, Anderson S, Tan-Chiu E et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19: 931-942.
41. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998; 3: 237-252.
42. Carney WP, Leitzel K, Ali S et al. HER-2/neu diagnostics in breast cancer. Breast Cancer Res 2007; 9: 207.
43. Demonty G, Bernard-Marty C, Puglisi F et al. Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer 2007; 43: 497-509.
44. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
45. Sunami E, Shinozaki M, Sim MS et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008; 10: R46.
46. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
47. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.